Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis

Nußbaumer, Barbara; Morgan, Laura C; Reichenpfader, Ursula; Greenblatt, Amy; Hansen, Richard A.; Noord, Megan Van; Lux, Linda J; Gartlehner, Gerald

doi:10.1007/s40263-014-0169-z

Cited by 17 publications

(9 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Focusing on HAMD‐21 treatment response (reduction of at least 50% in the HAMD‐21 sum score after six weeks of treatment), 35 patients were responder, while 13 patients were non‐responder (see Table 2 and Figure 1). The response rate in our sample (72.92%) was comparable to other studies (Milenkovic et al, 2017; Nussbaumer et al, 2014; Sarubin et al, 2014).…”

Section: Resultssupporting

confidence: 91%

The cytokine IL‐17A as a marker of treatment resistance in major depressive disorder?

Milenkovic

Sarubin

Hilbert

et al. 2019

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 91%

The cytokine IL‐17A as a marker of treatment resistance in major depressive disorder?

Milenkovic

Sarubin

Hilbert

et al. 2019

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…69 Extended-release antidepressants should be considered if adherence or compliance to medication is an issue.…”

Section: Are There Differences In Formulations Of Specific Antidepresmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

et al. 2016

View full text Add to dashboard Cite

Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals. Methods: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. ''Pharmacological Treatments'' is the third of six sections of the 2016 guidelines. With little new information on older medications, treatment recommendations focus on second-generation antidepressants.Results: Evidence-informed responses are given for 21 questions under 4 broad categories: 1) principles of pharmacological management, including individualized assessment of patient and medication factors for antidepressant selection, regular and

show abstract

“…The extended-release formulations of venlafaxine and paroxetine may be associated with lower rates of nausea than their immediate-release formulations [36]. However, a recent meta-analysis did not find significant differences in the rate of adverse events (including nausea) between immediate versus extended-release venlafaxine [37]. The data for the most recently approved antidepressant agents (i.e.…”

Section: Gastrointestinalmentioning

confidence: 99%

The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature

Carvalho

Sharma²,

Brunoni³

et al. 2016

Psychother Psychosom

508

324

View full text Add to dashboard Cite

Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later. They encompass gastrointestinal symptoms (nausea, diarrhea, gastric bleeding, dyspepsia), hepatotoxicity, weight gain and metabolic abnormalities, cardiovascular disturbances (heart rate, QT interval prolongation, hypertension, orthostatic hypotension), genitourinary symptoms (urinary retention, incontinence), sexual dysfunction, hyponatremia, osteoporosis and risk of fractures, bleeding, central nervous system disturbances (lowering of seizure threshold, extrapyramidal side effects, cognitive disturbances), sweating, sleep disturbances, affective disturbances (apathy, switches, paradoxical effects), ophthalmic manifestations (glaucoma, cataract) and hyperprolactinemia. At times, such adverse events may persist after drug discontinuation, yielding iatrogenic comorbidity. Other areas of concern involve suicidality, safety in overdose, discontinuation syndromes, risks during pregnancy and breast feeding, as well as risk of malignancies. Thus, the rational selection of ADs should consider the potential benefits and risks, likelihood of responsiveness to the treatment option and vulnerability to adverse events. The findings of this review should alert the physician to carefully review the appropriateness of AD prescription on an individual basis and to consider alternative treatments if available.

show abstract

Comparative Efficacy and Risk of Harms of Immediate- versus Extended-Release Second-Generation Antidepressants: A Systematic Review with Network Meta-Analysis

Cited by 17 publications

References 93 publications

The cytokine IL‐17A as a marker of treatment resistance in major depressive disorder?

The cytokine IL‐17A as a marker of treatment resistance in major depressive disorder?

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder

The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature

Contact Info

Product

Resources

About